Report: Tysabri Weighs on Biogen - WSJ.com
Links shared publicly online about this topic.
- 1,730total visits
Report: Tysabri Weighs on Biogen - WSJ.com
View full resource at online.wsj.com
Tags: Infection, Brain, Encephalitis, Tysabri
Most Recently Shared on September 22, 2009 at 4:10 pm By:
Report: Tysabri Concerns Will Weigh on Biogen http://bit.ly/LxVV5
FDA details timeframe of MS drug Tysabri's risks | Reuters
reuters.com — “WASHINGTON (Reuters) - The brain infection risk from Biogen Idec's multiple sclerosis drug Tysabri appears highest during the third year of treatment, U.S. health officials said in an updated warning released” View full resource at reuters.com
Most Recently Shared on April 22, 2011 at 4:36 pm By:
FDA reports on brain infections with MS drug Tysabri http://bit.ly/i1VSHB
FDA details timeframe of MS drug Tysabri's risks | Reuters
reuters.com — “WASHINGTON (Reuters) - The brain infection risk from Biogen Idec's multiple sclerosis drug Tysabri appears highest during the third year of treatment, U.S. health officials said in an updated warning released” View full resource at reuters.com
Most Recently Shared on April 22, 2011 at 4:29 pm By:
FDA reports on brain infections with MS drug Tysabri: WASHINGTON (Reuters) - More than 100 cases of a potentiall... http://bit.ly/gjJMhL
FDA details timeframe of MS drug Tysabri's risks | Reuters
reuters.com — “WASHINGTON (Reuters) - The brain infection risk from Biogen Idec's multiple sclerosis drug Tysabri appears highest during the third year of treatment, U.S. health officials said in an updated warning released” View full resource at reuters.com
Most Recently Shared on April 22, 2011 at 4:23 pm By:
FDA reports on brain infections with MS drug Tysabri: WASHINGTON (Reuters) - More than 100 cases o... http://bit.ly/i3C619 #health #news
Biogen: 7 More Infections, 1 More Death In Tysabri Patients
bioportfolio.com — “Nasdaq | By NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) reported 7 more cases of a rare brain infection among multiple sclerosis patients taking Tysabri, sol...” View full resource at bioportfolio.com
Most Recently Shared on March 18, 2011 at 8:53 pm By:
Article deleted already? @MS_Bio BioPortfolio News Biogen 7 More Infections 1 More Death In Tysabri Patients: Nasdaq http://bit.ly/e19NxE
Brass and Ivory: Life with Multiple Sclerosis and Rheumatoid Arthritis: European Medicines Agency recommends Gilenya (fingolimod), but rejects Fampyra (fampridine) and Movectro (cladribine)
brassandivory.org — “Brass and Ivory: Life with Multiple Sclerosis and Rheumatoid Arthritis: European Medicines Agency recommends Gilenya (fingolimod), but rejects Fampyra (fampridine) and Movectro (cladribine)” View full resource at brassandivory.org
Most Recently Shared on January 21, 2011 at 4:33 pm By:
European Medicines Agency recommends Gilenya (fingolimod), but rejects Fampyra (fampridine) and Movectro (cladri... http://bit.ly/dINvlp
Biogen reports four more Tysabri cases, one death | Reuters
reuters.com — “NEW YORK (Reuters) - Four more patients taking Biogen Idec's multiple sclerosis drug Tysabri have developed the serious brain infection known as PML and one of them died, according to the biotechnology” View full resource at reuters.com
Most Recently Shared on December 17, 2010 at 9:49 pm By:
Hisham Rana, MD Doctor and Physician
News: Biogen reports 4 new cases of potentially fatal progressive multifocal leukoencephalopathy http://reut.rs/hsf0aU - #health
Biogen reports more brain infections in MS patients | Reuters
reuters.com — “BOSTON (Reuters) - Two more patients taking Biogen Idec Inc's multiple sclerosis drug Tysabri have developed a potentially deadly brain infection known as PML, the company said on Wednesday. The Cambridge,” View full resource at reuters.com
Most Recently Shared on October 21, 2010 at 8:15 pm By:
Hisham Rana, MD Doctor and Physician
News: Biogen reports more brain infections in MS patients http://reut.rs/c0jCsJ - Progressive multifocal leukoencephalopathy (PML) #health
Multiple Sclerosis Patient-Reported Outcomes Study Shows Improvements In Quality Of Life Among Patients After 1 Year Of Treatment With TYSABRI | Psydir News
news.psydir.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measur...” View full resource at news.psydir.com
Most Recently Shared on April 17, 2010 at 2:02 pm By:
Multiple Sclerosis Patient-Reported Outcomes Study Shows Improvements In Quality Of Life… http://goo.gl/fb/8djOE
Multiple Sclerosis Patient-Reported Outcomes Study Shows Improvements In Quality Of Life Among Patients After 1 Year Of Treatment With TYSABRI
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) w” View full resource at medicalnewstoday.com
Most Recently Shared on April 17, 2010 at 1:05 pm By:
MNT Clinical Trials Health News
Multiple Sclerosis Patient-Reported Outcomes Study Shows Improvements In Quality Of Life Among Patients After 1 Year O... http://mnt.to/3BnJ
FDA warns of progressive multifocal leukoencephalopathy (PML) risk with Tysabri - MPR
empr.com — “The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients treated with Tysabri (natalizumab, from Biogen Idec).” View full resource at empr.com
Most Recently Shared on September 22, 2009 at 3:37 pm By:
MPR News: FDA warns of progressive multifocal leukoencephalopathy (PML) risk with Tysabri: The FDA cont.. http://bit.ly/ke2nc
Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients | Psydir News
news.psydir.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in conjunct...” View full resource at news.psydir.com
Most Recently Shared on September 14, 2009 at 12:32 pm By:
Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients http://ow.ly/15OWal
Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multi” View full resource at medicalnewstoday.com
Most Recently Shared on September 14, 2009 at 10:12 am By:
psychiatryrounds Psychiatry and Support
Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients: Biogen Idec (NASDAQ: BIIB) and .. http://bit.ly/jkuoc
Eighth Tysabri patient falls ill - The Boston Globe
boston.com — “NEW YORK - Biogen Idec Inc. said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year.” View full resource at boston.com
Most Recently Shared on June 13, 2009 at 1:40 pm By:
Scott Hensley Health Organization
Wonder if new FDA will revisit Tysabri. RT @GlobeBiz Eighth Tysabri patient falls ill w PML - http://is.gd/10ItT
MS Patients Report Greater Treatment Satisfaction With TYSABRI
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced interim results from an ongoing, one-year longitudinal health-outcomes study in which patients reported significantl” View full resource at medicalnewstoday.com
Most Recently Shared on May 29, 2009 at 2:29 pm By:
MedNewsToday: MS Patients Report Greater Treatment Satisfaction With TYSABRI: Biogen Idec (NASDAQ: .. http://tinyurl.com/nebo84
Advertisement
